O	0	5	Phase
O	6	9	III
O	10	15	trial
O	16	18	of
B-intervention	19	30	gemcitabine
I-intervention	31	35	plus
I-intervention	36	45	docetaxel
O	46	52	versus
B-control	53	65	capecitabine
I-control	66	70	plus
I-control	71	80	docetaxel
O	81	85	with
O	86	93	planned
O	94	103	crossover
O	104	106	to
O	107	110	the
O	111	120	alternate
O	121	127	single
O	128	133	agent
O	134	136	in
O	137	147	metastatic
O	148	154	breast
O	155	161	cancer
O	161	162	.

O	163	169	Safety
O	170	173	and
O	174	182	efficacy
O	183	185	of
O	186	197	gemcitabine
O	198	202	plus
O	203	212	docetaxel
O	213	214	(
O	214	216	GD
O	216	217	)
O	218	221	and
O	222	234	capecitabine
O	235	239	plus
O	240	249	docetaxel
O	250	251	(
O	251	253	CD
O	253	254	)
O	255	259	were
O	260	268	compared
O	269	271	in
B-eligibility	272	280	patients
I-eligibility	281	285	with
I-eligibility	286	296	metastatic
I-eligibility	297	303	breast
I-eligibility	304	310	cancer
O	310	311	,
O	312	317	where
O	318	321	the
O	322	331	alternate
O	332	341	crossover
O	342	353	monotherapy
O	354	355	(
O	355	357	GD
O	357	358	→
O	358	359	C
O	360	362	or
O	363	365	CD
O	365	366	→
O	366	367	G
O	367	368	)
O	369	372	was
O	373	386	predetermined
O	386	387	.

O	388	396	Patients
O	397	401	were
O	402	410	randomly
O	411	419	assigned
O	420	422	to
O	423	424	3
O	424	425	-
O	425	429	week
O	430	436	cycles
O	437	439	of
O	440	446	either
O	447	458	gemcitabine
O	459	463	1000
O	464	466	mg
O	466	467	/
O	467	468	m
O	468	469	(
O	469	470	2
O	470	471	)
O	472	474	on
O	475	479	days
O	480	481	1
O	482	485	and
O	486	487	8
O	488	492	plus
O	493	502	docetaxel
O	503	505	75
O	506	508	mg
O	508	509	/
O	509	510	m
O	510	511	(
O	511	512	2
O	512	513	)
O	514	516	on
O	517	520	day
O	521	522	1
O	523	525	or
O	526	538	capecitabine
O	539	543	1000
O	544	546	mg
O	546	547	/
O	547	548	m
O	548	549	(
O	549	550	2
O	550	551	)
O	552	557	twice
O	558	563	daily
O	564	566	on
O	567	571	days
O	572	573	1
O	573	574	-
O	574	576	14
O	577	581	plus
O	582	591	docetaxel
O	592	594	75
O	595	597	mg
O	597	598	/
O	598	599	m
O	599	600	(
O	600	601	2
O	601	602	)
O	603	606	day
O	607	608	1
O	608	609	.

O	610	614	Upon
O	615	626	progression
O	626	627	,
O	628	636	patients
O	637	645	received
O	646	655	crossover
O	656	667	monotherapy
O	667	668	.

O	669	676	Primary
O	677	680	end
O	681	686	point
O	687	690	was
B-outcome-Measure	691	695	time
I-outcome-Measure	696	698	to
I-outcome-Measure	699	710	progression
I-outcome-Measure	711	712	(
I-outcome-Measure	712	715	TtP
I-outcome-Measure	715	716	)
O	716	717	.

O	718	727	Secondary
O	728	731	end
O	732	738	points
O	739	748	evaluated
B-outcome-Measure	749	756	overall
I-outcome-Measure	757	765	response
I-outcome-Measure	766	770	rate
I-outcome-Measure	771	772	(
I-outcome-Measure	772	775	ORR
I-outcome-Measure	775	776	)
O	776	777	,
B-outcome-Measure	778	785	overall
I-outcome-Measure	786	794	survival
I-outcome-Measure	795	796	(
I-outcome-Measure	796	798	OS
I-outcome-Measure	798	799	)
O	799	800	,
O	801	804	and
B-outcome-Measure	805	812	adverse
I-outcome-Measure	813	819	events
I-outcome-Measure	820	821	(
I-outcome-Measure	821	824	AEs
I-outcome-Measure	824	825	)
O	825	826	.

O	827	834	Despite
O	835	839	over
O	839	840	-
O	840	847	accrual
O	848	850	of
B-total-participants	851	854	475
O	855	863	patients
O	863	864	,
O	865	868	the
O	869	874	trial
O	875	882	matured
O	883	887	with
O	888	892	only
B-total-participants	893	896	324
O	897	899	of
O	900	903	385
O	904	911	planned
O	912	915	TtP
O	916	922	events
O	923	926	due
O	927	929	to
O	930	937	patient
O	938	954	discontinuations
O	954	955	.

O	956	961	Human
O	962	971	epidermal
O	972	978	growth
O	979	985	factor
O	986	994	receptor
O	995	996	2
O	997	1003	status
O	1004	1007	was
O	1008	1011	not
O	1012	1020	captured
O	1021	1023	in
O	1024	1028	this
O	1029	1034	study
O	1034	1035	.

O	1036	1040	More
O	1041	1043	CD
O	1044	1052	patients
O	1053	1054	(
B-cv-bin-percent	1054	1056	28
I-cv-bin-percent	1056	1057	%
O	1057	1058	)
B-outcome	1059	1071	discontinued
I-outcome	1072	1075	due
I-outcome	1076	1078	to
I-outcome	1079	1082	AEs
O	1083	1087	than
O	1088	1090	GD
O	1091	1099	patients
O	1100	1101	(
B-iv-bin-percent	1101	1103	18
I-iv-bin-percent	1103	1104	.
I-iv-bin-percent	1104	1105	0
I-iv-bin-percent	1105	1106	%
O	1106	1107	,
O	1108	1109	P
O	1110	1111	=
O	1112	1113	0
O	1113	1114	.
O	1114	1117	009
O	1117	1118	)
O	1118	1119	.

B-outcome	1120	1123	TtP
O	1124	1125	[
O	1125	1131	hazard
O	1132	1137	ratio
O	1138	1139	(
O	1139	1141	HR
O	1141	1142	)
O	1143	1144	=
O	1145	1146	1
O	1146	1147	.
O	1147	1150	101
O	1150	1151	,
O	1152	1154	95
O	1154	1155	%
O	1156	1166	confidence
O	1167	1175	interval
O	1176	1177	(
O	1177	1179	CI
O	1179	1180	)
O	1181	1182	0
O	1182	1183	.
O	1183	1186	885
O	1186	1187	-
O	1187	1188	1
O	1188	1189	.
O	1189	1192	370
O	1192	1193	,
O	1194	1195	P
O	1196	1197	=
O	1198	1199	0
O	1199	1200	.
O	1200	1203	387
O	1203	1204	]
O	1205	1208	and
B-outcome	1209	1211	OS
O	1212	1213	(
O	1213	1215	HR
O	1216	1217	=
O	1218	1219	1
O	1219	1220	.
O	1220	1223	031
O	1223	1224	,
O	1225	1227	95
O	1227	1228	%
O	1229	1231	CI
O	1232	1233	0
O	1233	1234	.
O	1234	1237	830
O	1237	1238	-
O	1238	1239	1
O	1239	1240	.
O	1240	1243	280
O	1243	1244	,
O	1245	1246	P
O	1247	1248	=
O	1249	1250	0
O	1250	1251	.
O	1251	1254	785
O	1254	1255	)
O	1256	1260	were
O	1261	1264	not
O	1265	1278	significantly
O	1279	1288	different
O	1289	1298	comparing
O	1299	1301	GD
O	1302	1305	and
O	1306	1308	CD
O	1308	1309	.

B-outcome	1310	1313	ORR
O	1314	1317	was
O	1318	1321	not
O	1322	1335	statistically
O	1336	1345	different
O	1346	1347	(
O	1347	1348	P
O	1349	1350	=
O	1351	1352	0
O	1352	1353	.
O	1353	1356	239
O	1356	1357	)
O	1358	1367	comparing
O	1368	1370	GD
O	1371	1372	(
B-iv-bin-abs	1372	1374	72
O	1375	1377	of
B-intervention-participants	1378	1381	207
O	1381	1382	,
B-iv-bin-percent	1383	1385	34
I-iv-bin-percent	1385	1386	.
I-iv-bin-percent	1386	1387	8
I-iv-bin-percent	1387	1388	%
O	1388	1389	)
O	1390	1393	and
O	1394	1396	CD
O	1397	1398	(
B-cv-bin-abs	1398	1400	78
O	1401	1403	of
B-control-participants	1404	1407	191
O	1407	1408	,
B-cv-bin-percent	1409	1411	40
I-cv-bin-percent	1411	1412	.
I-cv-bin-percent	1412	1413	8
I-cv-bin-percent	1413	1414	%
O	1414	1415	)
O	1415	1416	.

B-outcome	1417	1420	TtP
I-outcome	1420	1421	,
I-outcome	1422	1424	OS
I-outcome	1424	1425	,
I-outcome	1426	1429	and
I-outcome	1430	1433	ORR
O	1434	1438	were
O	1439	1442	not
O	1443	1456	significantly
O	1457	1466	different
O	1467	1476	comparing
O	1477	1486	crossover
O	1487	1493	groups
O	1493	1494	.

O	1495	1497	GD
O	1498	1504	caused
O	1505	1512	greater
B-outcome	1513	1520	fatigue
O	1520	1521	,
B-outcome	1522	1536	hepatotoxicity
O	1536	1537	,
B-outcome	1538	1549	neutropenia
O	1549	1550	,
O	1551	1554	and
B-outcome	1555	1571	thrombocytopenia
O	1572	1575	but
O	1576	1579	not
B-outcome	1580	1587	febrile
I-outcome	1588	1599	neutropenia
O	1599	1600	;
O	1601	1603	CD
O	1604	1610	caused
O	1611	1615	more
B-outcome	1616	1620	hand
I-outcome	1620	1621	-
I-outcome	1621	1625	foot
I-outcome	1626	1634	syndrome
O	1634	1635	,
B-outcome	1636	1652	gastrointestinal
I-outcome	1653	1661	toxicity
O	1661	1662	,
O	1663	1666	and
B-outcome	1667	1676	mucositis
O	1676	1677	.

O	1678	1680	GD
O	1681	1684	and
O	1685	1687	CD
O	1688	1696	produced
O	1697	1704	similar
O	1705	1713	efficacy
O	1714	1717	and
O	1718	1726	toxicity
O	1727	1735	profiles
O	1736	1746	consistent
O	1747	1751	with
O	1752	1757	prior
O	1758	1766	clinical
O	1767	1777	experience
O	1777	1778	.
